Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).

货号（Catalog No.）

CSD00331

通用名INN

Lifastuzumab Vedotin

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer pH7.5

Source

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

生物活性

产品描述(Description)

Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).

别名(Alternative names)

DNIB0600A (conjugate),MNIB2126A (non conjugate)

靶点;物种(Specificity target name;species)

SLC34A2[Homo sapiens]

种类(Species)

Humanized

受体鉴定(Receptor identification)

IgG1-kappa

化学信息

CAS

1401812-88-1

存储条件(Storage)

store at -80°C